Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42

Benzinga Newsdesk www.benzinga.com Positive 54.4%

Neg 0% Neu 0% Pos 54.4%

Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.